IMI to hold annual shareholders' meeting on June 16, 2004 TORONTO, June 8 /PRNewswire-FirstCall/ -- IMI International Medical Innovations Inc. (TSX:IMI; Amex: IME), a world leader in predictive medicine, will hold its annual shareholders' meeting on Wednesday, June 16, 2004 at 10:30 a.m. (ET) at the Toronto Stock Exchange Conference Centre, located at 130 King Street West, in Toronto, Ontario. Following the formal meeting, Dr. Brent Norton, President and Chief Executive Officer, will discuss IMI's operating performance and recent activities, and provide an outlook for fiscal 2004 and beyond. In addition, the company will demonstrate its lead product, PREVU(x) Coronary Heart Disease Predictor, which measures an individual's risk of cardiovascular disease by testing the amount of sterol, or cholesterol, in skin tissue. IMI recently announced an exclusive worldwide non-Canadian licensing agreement with McNeil Consumer Healthcare, a Johnson & Johnson company, for this cardiovascular risk assessment technology. For those unable to attend in person, the meeting will be webcast and subsequently archived at http://www.imimedical.com/ or http://www.newswire.ca/. The full proceedings will be streamed in real time, with accompanying slides. Instructions for accessing the event will be provided on both websites. About IMI IMI is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The company's head office is located in Toronto, and its research and product development facility is at McMaster University in Hamilton, Ontario. For further information, please visit the company's website at http://www.imimedical.com/. This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings. DATASOURCE: IMI International Medical Innovations Inc. CONTACT: Sarah Borg-Olivier, Director, Communications, T: (416) 222-3449,

Copyright